Microglial activation states (DAM, ARM, IRM); TREM2 risk variant; complement-mediated synapse loss (Stevens 2007); inflammation as drug target.
Microglial activation states (DAM, ARM, IRM); TREM2 risk variant; complement-mediated synapse loss (Stevens 2007); inflammation as drug target.